Caprelsa 300mg tablets (Vandetanib) | MHP
CAPRELSA 300MG
DESCRIPTION:
Vandetanib is sold under the brand name Caprelsa 300mg.Caprelsa 300mg consist of broad spectrum, orally available kinase inhibitor that targets mainly tyrosine kinases, containing vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range.
Caprelsa 300mg which is used as prescription drug under the guidance of medical practioners
INDICATION:
Indicated for the therapy of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.MECHANISM OF ACTION:
Vandetanib belongs to type of targeted therapy called a tyrosine kinase inhibitor.A kinase is an enzyme which helps to cell growth. This means it mechanism by targeting receptors present on the cancer cells. Vandetanib aims epidermal growth factor (EGFR) and vascular endothelial growth factor receptors (VEGF).
It stops tumor growth and the development of a blood supply to the tumor (angiogenesis).
 |
| CAPRELSA 300MG |
PRODUCT DEATIALS:
Brand :Caprelsa
Ingredients : Vandetanib
Strength : 300mg
Manufactured : Genzyme Corp
Package : 30 film tablets
ADME:
Absorption: Duration to maximum plasma level is 6 hr (range 4-10 hr) and steady state is 3 monthsDistribution: Bounding of plasma protein is 90% and volume of distribution is 7450L
Metabolism: Caprelsa 300mg is metabolized by CYP3A4
Elimination: The drug elimination through feces 44% and via urine collection period of 21 day after single dose.
Half-life 19 days
DOSAGE MANAGMANT:
The Caprelsa prescribed dose for medullary thyroid cancer is 300mg administrated orally once daily until disease progression or unacceptable toxicity occurs.Avoid the tablets crushing, disperse the tablet in 2 ounces of water by stirring 10 minutes approximately.
Be cautious, avoid use other liquids for dispersion and swallow the medicine soon after dispersion, if any remaining residue with 4 additional ounces of water and swallow.
Th dispersion liquid can be administrated via nasogastric or gastrostomy tubes.
PRECAUTIONS:
The drug Caprelsa 300mg using for treatment which will have Effective CYP3A4 inducers decreased exposure to Vandetanib by up to 40%; however, no clinically significant effect on exposure to Vandetanib was resulted in the presence of the effective CYP3A4 inhibitors.While on treatment with Caprelsa 300mg producing Fatal skin reactions, involving with Stevens-Johnson syndrome and serious toxic epidermal necrolysis resulted; systemic treatment such as corticosteroids may be required; permanently blocks therapy for severe skin reactions.
While on treatment with Caprelsa 300mg will produce Interstitial lung disease (ILD), causes in death has been reported; interfere with Vandetanib and examine unexplained Dyspnea, cough, and fever; applicable measures should be taken for ILD
When on treatment with Caprelsa 300mg will causes Ischemic cerebrovascular events, haemorrhage, heart failure, diarrhea, hypothyroidism, hypertension, and reversible posterior leukoencephalopathy syndrome,.
Due to the drug Caprelsa 300mg can cause fetal harm when administered to pregnant women; advise not to become pregnancy while getting caprelsa and for 4 months following treatment
SIDE EFFECTS:
Caprelsa 300mg has some side effects as follows :Headache, Fatigue, Kidney problems, Dry skin, Vomiting, Weakness, Irregular heart beat, Difficulty sleeping, Low blood sugar, Abdominal pain, Poor appetite, Weight loss, Diarrhea, Rash, Elevated Liver Enzymes (ALT), Low calcium levels, Acne, High blood pressure, Nausea, Low white blood cell count, Photosensitivity (sensitivity to sunlight), Bleeding, Anemia, Liver tests increased (bilirubin), Itching, Heartburn, Cough, Upper respiratory infection, Depression.
DRUG INTERACTION:
While concomitant use with a strong CYP3A4 inducer will reduces Vandetanib plasma concentration. Therefore, avoid combination of known strong CYP3A4 inducers duringCaprelsa 300mg treatment.
When treatment with Caprelsa 300mg that are transported by OCT2 will increased plasma concentration of metformin.When combination of Caprelsa 300mg with digoxin will increased plasma concentration of digoxin.
Avoid combination of Caprelsa 300mg with agents which may prolong the QT interval.
CONTRAINDICATION:
Congenital long QT syndrome.PREGNANCY:
Pregnancy category DCaprelsa 300mg is embryotoxic and fetotoxic, because of pharmacological action treatment will causes harm to fetal when administered to a pregnant woman
LACTATION:
During treatment Advise females not to breastfeed for 4 months after final dose.STORAGE:
Caprelsa 300mg tablets should be stored at 25°C.MISSED DOSE:
If dose is missed to take, then administer the dose immediate before reach of next dose time or swap the missed dose and follow the normal schedule. Do not take missed dose within 12 hours of the next dose.Should consult the doctor about missed dose and overdose.
Comments
Post a Comment